In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
Prostate cancer patients who undergo radiation treatment, especially brachytherapy, are at increased relative risk of bladder cancer.
Higher radiation doses are critical to optimizing long-term outcomes following brachytherapy for prostate cancer (PCa).
Carbohydrate restriction may be effective in ameliorating adverse effects associated with androgen-deprivation therapy (ADT) for prostate cancer.
Patients with cT1a and cT1b prostate tumors have favorable long-term outcomes after radical prostatectomy (RP).
Baseline PSA levels in men aged 55-60 years strongly predict the future risk of being diagnosed with prostate cancer (PCa).
Salvage radical prostatectomy (SRP) offers good long-term oncologic outcomes among patients who experience recurrence.
Dr Neal Shore spoke with Cancer Therapy Advisor about the place of radium-223 in the therapeutic armamentarium and how he uses the drug in his practice.